US Subpoena For Sun Amid Pricing Heat
This article was originally published in PharmAsia News
US lawmakers continue to scrutinize drug firms amid ongoing concerns over price-related issues and their impact on healthcare costs. The US Justice Department’s antitrust division has now subpoenaed Sun Pharma for information pertaining to generic drugs, pricing and certain company records, though the Indian firm claimed the move would have no immediate impact on its earnings.
You may also be interested in...
Few would argue that 2016 threw a number of curveballs into the global arena. With the New Year upon us, Scrip took a deep breath and asked a number of internal and external contributors across the pharma and biotech spectrum for their expectations for 2017.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.